IJCRR - 7(18), September, 2015
PHYSIOCHEMICAL PROPERTIES OF SOME PAEDIATRIC FORMULATIONS OF ARTEMETHER -LUMEFANTRINE PRESCRIBED FOR UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA.
Author: Awofisayo Sunday O., Okhamafe Augustine O., Arhewoh Mathew I.
Physicochemical properties bothering on the quality of powder for paediatric suspension (PPS) of artemether-lumefantrine (AL) were evaluated. The moisture content, viscosity, total solid and chemical contents were determined. The assay was analyzed simultaneously for artemether and lumefantrine using high pressure liquid chromatography (chromosil C18 column/ UV detection at 216 nm). Acetonitrile: 25 mM potassium dihydrogen phosphate (70: 30%, v/v) and nevirapine served as mobile phase and internal standard, respectively. Statistical analysis was done using students t-test to compare the parameters for the products at CI, 95%. The artemether and lumefantrine contents varied from 40.3-112.54% and 71.9 – 91.4%, respectively. The range of values (mean) of moisture content, viscosity, pH and total solid were 2.9-6.9 (4.68)% , 99.1-193.8(124.7) mPa.s, 3.5-7.8 (4.7) and 93.1- 97.1 (95.3) %, respectively. The results showed statistical different outcomes (P < 0.05). PPS products sampled vary widely in their physicochemical properties.
Keywords: Artemether-lumefantrine, Paediatric formulations, Physicochemical properties, Uncomplicated malaria
Awofisayo Sunday O., Okhamafe Augustine O., Arhewoh Mathew I.. PHYSIOCHEMICAL PROPERTIES OF SOME PAEDIATRIC FORMULATIONS OF ARTEMETHER -LUMEFANTRINE PRESCRIBED FOR UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA. International Journal of Current Research and Review. 7(18), September, 41-45
1. Amin A.A., Kokwaro G.O. 2007. Antimalarial drug quality in Africa. J Clin PharmTherap, 32: 429–440.
2. Awofisayo S.O., Willie E., Umoh E. 2010. Quality control evaluation of multi-source artemether- lumefantrine tablets prescribed for uncomplicated multi-drug resistant malaria. Ind J Nov Drug Del, 4: 153-157.
3. Bapner J.S., Tripathi C.D., Tekur U.1996. Drug utilization pattern in third world. Pharmaco-economics, 9:286-294.
4. Cesar I.C, Pianetti G.A. 2009. Quantitation of artemether in pharmaceutical raw material and injections by high performance liquid chromatography. Braz J Pharm Sci., 45: 738-742.
5. European Medicine Evaluation Agency (EMEA). 2006. EMEA/ CHMP/PEG/19481/2005. Reflection paper formulation of choice for the paediatric population; EMEA, London.
6. Food and Drug Administration (FDA). 2007. Food and Drug Administration Amendments Act, FDA, Silver Spring.
7. Helin-Tanninen M., Naaranlahti T., Kontra K., Wallenius K. 2007. Enteral suspension of nifedipine for neonates. Part 1. Formulation of nifedipine suspension for hospital use. J Clin Pharm Therap., 26: 49–57.
8. Khalil I.F., Abildrup U., Alifrangis L.H. 2011. Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal., 54:168–172.
9. Lavoie F., Cartilier L., Thibert R. 2002. New methods characterizing avalanche behaviour to determine powder flow. Pharm Res.,19: 887-893.
10. Pingala S.G., Mangaonkar K.V. 2013. Quantification of lumefantrine in human plasma using LC-MS/MS and its application to bioequivalence study. J Pharm., 13:1-8.
11. Sridhar B., Rao K.H., Srinivas T.V. 2010. A validated reverse phase HPLC method for the simultaneous estimation of artemether and lumefantrine in pharmaceutical dosage forms. Int J Adv Pharm Sci., 1: 95-99.
12. United States Pharmacopoeia. 2014. The National Formulary, USP 38 NF13; United States Pharmacopeia Convention, Inc.: Rockville, MD, USA.
13. Vandercruyssen K., D’Hont M., Vergote V. 2004. LC-UV/MS Quality analytics of paediatrics artemether formulations. J Pharm Anal., 4 (I): 37 – 52.
14. World Health Organization. 2006. Counterfeit Medicines. Facts sheet no 275. 2006. Revised February 2006.
15. World Health Organization. 1999. Counterfeit Drugs; Guidelines for the development of measures to combat counterfeit drugs. Geneva: WHO, pp 1 – 60.
16. World Health Organization. 2013. World Malaria Report; Geneva, Switzerland.
17. Zajieek A. 2009. The national institutes of health and the best pharmaceuticals for children act. Paed Drugs., (II): 45 – 47.